|
C3ORF26 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.67721392330122E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.08162434143378E-14 |
| Normal-vs-Stage2 |
5.014799999703E-07 |
| Normal-vs-Stage3 |
6.95639990055952E-10 |
| Normal-vs-Stage4 |
3.57539997608569E-10 |
| Stage1-vs-Stage2 |
8.987200E-01 |
| Stage1-vs-Stage3 |
5.981000E-01 |
| Stage1-vs-Stage4 |
8.984600E-01 |
| Stage2-vs-Stage3 |
8.294600E-01 |
| Stage2-vs-Stage4 |
9.936400E-01 |
| Stage3-vs-Stage4 |
7.786400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.4077627952247E-13 |
| Normal-vs-AfricanAmerican |
5.59339999983699E-07 |
| Normal-vs-Asian |
1.05510000003584E-06 |
| Caucasian-vs-AfricanAmerican |
8.889600E-01 |
| Caucasian-vs-Asian |
3.846400E-01 |
| AfricanAmerican-vs-Asian |
6.570800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.00870439673417E-14 |
| Normal-vs-Female |
4.13746814587057E-12 |
| Male-vs-Female |
4.516600E-03 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.20525852923492E-12 |
| Normal-vs-Age(41-60Yrs) |
1.48414613931891E-12 |
| Normal-vs-Age(61-80Yrs) |
4.57869964165525E-10 |
| Normal-vs-Age(81-100Yrs) |
6.262100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.559400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.879000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.348200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.504800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.372200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.577800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.189500E-02 |
| Classical-VS-Follicular |
9.237900E-03 |
| Classical-VS-Other |
2.184000E-01 |
| Classical-VS-Normal |
2.57449617180328E-12 |
| Tall-VS-Follicular |
1.738760E-03 |
| Tall-VS-Other |
5.561700E-02 |
| Tall-VS-Normal |
9.378200E-04 |
| Follicular-VS-Other |
9.259000E-01 |
| Follicular-VS-Normal |
2.01982874870055E-12 |
| Other-VS-Normal |
1.435370E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.81987758196556E-12 |
| Normal-vs-N1 |
4.69900007793456E-10 |
| N0-vs-N1 |
7.427600E-01 |
|
|
